Most teams hunt patents too late. The real advantage is finding design-around opportunities before the market even notices.
If you’re building a pipeline, launching a product, or investing in generics/biosimilars, you already know the obvious: formulat…

Russia’s latest VED/SSM list update isn’t just another regulatory footnote—it’s a live-fire signal to anyone planning generic launches into the Russian market.
Here’s the agitation: in pharma, timing isn’t a “nice-to-have.” It’s the difference between …

Pharma pipelines don’t fail because of science. They fail because of risk you didn’t model.
That’s the uncomfortable truth behind Freedom-to-Operate (FTO): it’s not a checkbox exercise—it’s the discipline that keeps your next launch from becoming your …

Beyond the ANDA: How the 505(b)(2) Pathway Can Build Differentiated Drugs—and Defend Them
Most pharma teams treat the 505(b)(2) pathway like a “regulatory workaround.” A way to move faster, lean on existing data, and avoid the full burden of a brand-ne…

Pharma IP teams are used to thinking in timelines: filing windows, priority dates, prosecution milestones, and—eventually—patent expiry. But in Russia, the clock is increasingly being shaped by something less predictable than a calendar: how patent ter…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
In pharma, “good patents” are often treated like a finish line. File the application, get the grant, move on. But the market doesn’t reward paperwork—it re…

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical market, timing is everything. Patent cliffs don’t just change drug prices; they reshape formularies, bargaining power, and the entire economics of ca…

Generic launches don’t “just happen.” They arrive on a calendar built by patents, litigation, and regulatory timing.
If you’re still forecasting generic drug launch dates by looking at last quarter’s sales trends or generic “rumors,” you’re already b…

Most people “mine” the FDA Orange Book for patents. Few mine it for people.
Here’s the uncomfortable truth: the Orange Book isn’t just a database of drug approvals—it’s a map of who builds the pipeline, who files the claims, and who quietly accumulates…

Biotech investors love “pipeline quality.” But portfolio winners are often built on something less glamorous: how you rank projects when capital is scarce and timelines are uncertain.
That’s where two finance concepts—Net Present Value (NPV) and the Pr…